In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin.
The human tumor stem-cell assay was used to investigate the in vitro chemosensitivity of 27 evaluable samples to cisplatin and its analogues, iproplatin and carboplatin, as well as to BCNU, teniposide, vindesine, and dibromodulcitol. All agents exhibited some antitumor activity with the exception of dibromodulcitol (zero response out of 19 evaluable samples). Vindesine, BCNU, and carboplatin were the three most active compounds, with response rates of 29%, 23%, and 22%, respectively. There was a lack of complete cross-resistance between carboplatin and cisplatin as well as between carboplatin and BCNU. Our data suggest that clinical studies with carboplatin and combinations of vindesine plus cisplatin and its analogues may be worthwhile.
Dodion
P
P
Laboratoire d'Investigation Clinique H. J. Tagnon, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Sanders
C
C
Georges
P
P
Kenis
Y
Y
D001932:Brain Neoplasms / Q000188:drug therapy*; D016190:Carboplatin; D002330:Carmustine / Q000494:pharmacology; D002945:Cisplatin / Q000494:pharmacology*; D003114:Colony-Forming Units Assay; D004351:Drug Resistance; D006801:Humans; D008936:Mitolactol / Q000494:pharmacology; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D013713:Teniposide / Q000494:pharmacology; D014410:Tumor Stem Cell Assay; D014751:Vindesine / Q000494:pharmacology
D009944:Organoplatinum Compounds; C023359:iproplatin; D013713:Teniposide; D016190:Carboplatin; D008936:Mitolactol; D002945:Cisplatin; D014751:Vindesine; D002330:Carmustine